Crowe J, Christensen E, Smith M, Cochrane M, Ranek L, Watkinson G, Doniach D, Popper H, Tygstrup N, Williams R
Gastroenterology. 1980 May;78(5 Pt 1):1005-10.
The effects of azathioprine on the course of primary biliary cirrhosis were studied prospectively in a multinational, double-blind randomized clinical trial involving 236 patients, of which 124 received azathioprine and 112 placebo. No significant effects were seen on survival, clinical course, hepatic histologic features, hepatic tests, or immunologic abnormalities after a median follow-up period of 18 mo, but most of the trends observed were in favor of azathioprine. The results obtained so far indicate that the effect of azathioprine as a single treatment is limited and probably of little clinical importance, but more years of follow-up will be needed to provide a definite conclusion.
在一项涉及236例患者的多国双盲随机临床试验中,对硫唑嘌呤对原发性胆汁性肝硬化病程的影响进行了前瞻性研究,其中124例接受硫唑嘌呤治疗,112例接受安慰剂治疗。中位随访期18个月后,在生存、临床病程、肝脏组织学特征、肝功能检查或免疫异常方面未观察到显著影响,但观察到的大多数趋势都有利于硫唑嘌呤。目前获得的结果表明,硫唑嘌呤作为单一治疗的效果有限,可能临床意义不大,但需要更多年的随访才能得出明确结论。